October 24, 2017 10:16 AM EDT
Financing

Eye­ing a big heart fail­ure mar­ket, scPhar­ma­ceu­ti­cals aims for $100M IPO

John Carroll

Editor & Founder

Af­ter lin­ing up an ap­pli­ca­tion for FDA ap­proval of a new ap­proach to treat­ing flu­id re­ten­tion in heart fail­ure pa­tients a few months ago, Burling­ton …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Nor­bert Bischof­berg­er's time as Kro­nos CEO ends as biotech seeks new life

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

To lead NIH, Trump taps Stan­ford aca­d­e­m­ic and pan­dem­ic re­sponse crit­ic Jay Bhat­tacharya

A service from the Financial Times